The PD-1/PD-L1 signaling pathway has been extensively studied in the context of tumor diseases, and blockade of the pathway with checkpoint inhibitors has promise for the treatment of many forms of cancer (Sharma and Allison, 2015). This evidence concerns the gene PDCD1 and cancer.